Table 2.
In vitro efficacy of tixagevimab and cilgavimab against SARS-CoV-2 variants of concern (VOC). Arrows indicate fold-reductions in neutralizing activity compared to wild-type D614G strain (e.g., Wuhan-Hu-1, USA-WA1/2020, B.1, or other reference strains) (=no reduction; ↓: 1–3 fold reduction; ↓↓: 3–5 fold reduction; ↓↓↓: >5 fold reduction). PHE: Public Health England.
| WHO VOC | Alpha | Beta | Gamma | Delta | Omicron | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PANGOLIN name | B.1.1.7 | B.1.351 | P.1 | B.1.617.2 | BA.1 | BA.2 | BA.2.12.1 | BA.2.75 | BA.4/BA.5 | BA.4.6 | BA.4.7 | BA.5.9 |
| NextStrain name | 20I/S:501Y.V1 | 20H/S:501Y.V2 | 20J/S:501Y.V3 | 21A/S:478K and descendants 21I/21J | 21K (descendant of 21M) | 21L (descendant of 21M) | 22C | 22D | 22A/22B | - | - | - |
| UKHSA/PHE name | VOC-20DEC-01 | VOC-20DEC-02 | VOC-21JAN-02 | VUI-21APR02 | VUI-21NOV-01 | VUI-22JAN-01 | - | V-22JUL-1 | VOC-22APR-03/VOC-22APR-04 | - | - | - |
| GISAID name | GRY (formerly GR/501Y.V1) | GH/501Y.V2 | GR/501Y.V3 | G/452R.V3 | GRA (formerly GR/484A) | |||||||
| tixagevimab /AZD8895/COV2-2196 | ↓↓↓ [47] | ↓↓↓ [47] | = [48] | = [27,49,50,51,52,53,54] | ↓↓↓ [25,41,53,54,55,56,57,58,59,60] | ↓↓↓ [26,41,58,59,60,61,62,63,64] (including BA.2.11, BA.2 L452Q, BA.2 S704L, BA.2 HV69-70del, BA.2 F486V, BA.2 R493Q [60]) | ↓↓↓ [41,58,60,63,64] | ↓↓↓ [62,63,64,65,66] | ↓↓↓ [41,58,59,60,62,63,64] | ↓↓↓ [67,68] | ↓↓↓ [67,68] | ↓↓↓ [67,68] |
| cilgavimab /AZD1061/COV2-2130 | = [47] | = [47] | = [48] | ↓ [27,49,50,51,52,53,54] | ↓↓↓ [24,25,53,55,56,57,58,59,60] | ↓ [26,41,58,59,60,61,62,63,64] (including BA.2.11, BA.2 L452Q, BA.2 S704L, BA.2 HV69-70del, BA.2 F486V, BA.2 R493Q [60]) | ↓ [41,58,60,63,64] | ↓↓↓ [62,63,64,65,66] | ↓↓ [41,58,59,60,62,63,64,69] | ↓↓↓ [67,68] | ↓↓↓ [67,68] | ↓↓↓ [67,68] |